DK1280540T3 - Modificeret faktor VIII - Google Patents

Modificeret faktor VIII

Info

Publication number: DK1280540T3
Authority: DK; Denmark
Prior art keywords: factor viii; modified factor; inhibitory antibodies; amino acid; modified
Prior art date: 2000-03-10

Application number

DK01910853T

Other languages

Danish (da)

English (en)

Inventor

John S Lollar

Original Assignee

Univ Emory

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-10

Filing date

2001-02-16

Publication date

2008-07-14

2001-02-16 Application filed by Univ Emory filed Critical Univ Emory

2008-07-14 Application granted granted Critical

2008-07-14 Publication of DK1280540T3 publication Critical patent/DK1280540T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Glass Compositions (AREA)
Fish Paste Products (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Steroid Compounds (AREA)

DK01910853T 2000-03-10 2001-02-16 Modificeret faktor VIII DK1280540T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/523,656 US6458563B1 (en)	1996-06-26	2000-03-10	Modified factor VIII
PCT/US2001/005076 WO2001068109A1 (fr)	2000-03-10	2001-02-16	Facteur viii modifie

Publications (1)

Publication Number	Publication Date
DK1280540T3 true DK1280540T3 (da)	2008-07-14

Family

ID=24085870

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01910853T DK1280540T3 (da)	2000-03-10	2001-02-16	Modificeret faktor VIII

Country Status (35)

Country	Link
US (3)	US6458563B1 (fr)
EP (1)	EP1280540B1 (fr)
JP (1)	JP4044337B2 (fr)
KR (1)	KR100485525B1 (fr)
CN (1)	CN1191360C (fr)
AT (1)	ATE391512T1 (fr)
AU (2)	AU2001238416B2 (fr)
BE (1)	BE2016C024I2 (fr)
BR (2)	BR122013026957A8 (fr)
CA (1)	CA2400295C (fr)
CY (2)	CY1108179T1 (fr)
CZ (1)	CZ298250B6 (fr)
DE (1)	DE60133541T2 (fr)
DK (1)	DK1280540T3 (fr)
EE (1)	EE05075B1 (fr)
ES (1)	ES2304379T3 (fr)
FR (1)	FR16C0016I2 (fr)
HU (2)	HU227804B1 (fr)
IL (2)	IL151371A0 (fr)
LT (1)	LTC1280540I2 (fr)
LU (1)	LU93049I2 (fr)
ME (1)	ME00601B (fr)
MX (1)	MXPA02008798A (fr)
NL (1)	NL300808I2 (fr)
NO (2)	NO331935B1 (fr)
NZ (1)	NZ520799A (fr)
PL (1)	PL202936B1 (fr)
PT (1)	PT1280540E (fr)
RS (1)	RS50364B (fr)
RU (1)	RU2285724C2 (fr)
SI (1)	SI1280540T1 (fr)
SK (1)	SK286205B6 (fr)
UA (1)	UA75064C2 (fr)
WO (1)	WO2001068109A1 (fr)
ZA (1)	ZA200206810B (fr)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7560107B2 (en)	1996-06-26	2009-07-14	Emory University	Modified factor VIII
JP2005518181A (ja) *	2001-01-12	2005-06-23	ジ・アメリカン・ナショナル・レッド・クロス	第ｖｉｉｉ因子のヘパラン硫酸プロテオグリカン仲介性クリアランスを低下させるための方法および組成物
CA2461443C (fr) *	2001-10-05	2011-07-12	Emory University	Sequences d'acides nucleiques et d'acides amines codant des polypeptides de facteur viii a expresseur a haut rendement et leurs procedes d'utilisation
MXPA04005079A (es) *	2001-11-30	2004-08-19	Univ Emory	Variantes del dominio c2 del factor viii.
GB0207092D0 (en) *	2002-03-26	2002-05-08	Sod Conseils Rech Applic	Stable pharmaceutical composition containing factor VIII
TWI353991B (en)	2003-05-06	2011-12-11	Syntonix Pharmaceuticals Inc	Immunoglobulin chimeric monomer-dimer hybrids
US7709224B2 (en) *	2003-06-03	2010-05-04	Biosante Pharmaceuticals, Inc.	Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US7485291B2 (en) *	2003-06-03	2009-02-03	Cell Genesys, Inc.	Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
EP1636261B1 (fr) *	2003-06-26	2007-08-01	MERCK PATENT GmbH	Proteines de thrombopoietine a proprietes ameliorees
US20050059023A1 (en) *	2003-09-16	2005-03-17	Cantor Thomas L.	Methods and kits for monitoring resistance to therapeutic agents
US7211559B2 (en) *	2003-10-31	2007-05-01	University Of Maryland, Baltimore	Factor VIII compositions and methods
US7855274B2 (en) *	2003-12-03	2010-12-21	University Of Rochester	Recombinant factor VIII having increased specific activity
EP1750733B1 (fr) *	2004-05-03	2013-12-11	Emory University	Methode d'administration de facteur viii sans domaine b porcin
WO2005123928A1 (fr) *	2004-06-08	2005-12-29	Battelle Memorial Institute	Production du facteur viii de coagulation humain à partir de cellules végétales et de plantes entières
SI1824988T1 (sl) *	2004-11-12	2017-11-30	Bayer Healthcare Llc	Usmerjena modifikacija FVIII
WO2006063031A2 (fr)	2004-12-06	2006-06-15	Haplomics	Variants alleliques du facteur viii humain
US7855279B2 (en)	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
EP1968999A2 (fr)	2005-12-07	2008-09-17	Technische Universität München	Petits ligands d'affinite peptidiques et peptido-mimetiques pour le facteur viii et pour des proteines similaires au facteur viii
EP1816201A1 (fr)	2006-02-06	2007-08-08	CSL Behring GmbH	Facteur de coagulation VIIa modifié ayant une stabilité 'half-life' améliorée
DE602007007923D1 (de) *	2006-04-11	2010-09-02	Csl Behring Gmbh	Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide
US7939632B2 (en) *	2006-06-14	2011-05-10	Csl Behring Gmbh	Proteolytically cleavable fusion proteins with high molar specific activity
EP3231440A1 (fr) *	2006-12-22	2017-10-18	CSL Behring GmbH	Facteurs de coagulation modifiés avec une demi-vie in vivo prolongée
EP1935430A1 (fr) *	2006-12-22	2008-06-25	CSL Behring GmbH	Facteurs de coagulation modifiés avec une demi-vie in vivo prolongée
FR2913020B1 (fr) *	2007-02-23	2012-11-23	Biomethodes	Nouveaux facteurs viii pour le traitement des hemophiles de type a
EP1988101A1 (fr) *	2007-05-04	2008-11-05	Novo Nordisk A/S	Amélioration des titres de polypeptide de facteur VIII dans les cultures cellulaires
CA2703948A1 (fr) *	2007-11-01	2009-05-07	University Of Rochester	Facteur viii recombinant ayant une stabilite accrue
EP2149603A1 (fr)	2008-07-28	2010-02-03	DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH	Variantes du facteur IX dotées d'activité de coagulation en l'absence de leur cofacteur et leur utilisation pour le traitement de troubles du sang
WO2010091122A1 (fr)	2009-02-03	2010-08-12	Amunix, Inc.	Polypeptides recombinants étendus et compositions les comprenant
SI2440239T1 (en)	2009-06-09	2018-01-31	Prolong Pharmaceuticals, LLC	Hemoglobin compositions
BR112012004094A2 (pt)	2009-08-24	2016-03-08	Amunix Operating Inc	composições de fator vii de coagulação e métodos para fazer e usar as mesmas
EP2498804A4 (fr) *	2009-11-13	2013-05-08	Puget Sound Blood Ct	Variants d'épitopes des lymphocytes t du facteur viii à immunogénicité réduite
MX353233B (es)	2009-12-06	2018-01-08	Bioverativ Therapeutics Inc	Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos.
US20110177107A1 (en) *	2010-01-14	2011-07-21	Haplomics, Inc.	Predicting and reducing alloimmunogenicity of protein therapeutics
US9611310B2 (en)	2010-07-09	2017-04-04	Bioverativ Therapeutics Inc.	Systems for factor VIII processing and methods thereof
WO2012006635A1 (fr)	2010-07-09	2012-01-12	Biogen Idec Hemophilia Inc.	Molécules à chaîne unique pouvant être traitées et polypeptides faits à partir de celles-ci
US9150637B2 (en)	2010-11-05	2015-10-06	Baxalta Inc.	Variant of antihemophilic factor VIII having increased specific activity
BR112013017281A2 (pt) *	2011-01-05	2016-09-20	Expression Therapeutics Llc	método e sistema para cultura de células em suspensão
DK2717898T3 (en)	2011-06-10	2019-03-25	Bioverativ Therapeutics Inc	COAGULATING COMPOUNDS AND PROCEDURES FOR USE THEREOF
DK3513804T3 (da)	2011-07-08	2022-06-20	Bioverativ Therapeutics Inc	Kimære og hybride faktor viii-polypeptider og fremgangsmåder til anvendelse deraf
US10656167B2 (en)	2011-07-25	2020-05-19	Bioverativ Therapeutics Inc.	Assays to monitor bleeding disorders
CN102277379B (zh) *	2011-08-18	2013-07-24	中国科学院遗传与发育生物学研究所	表达凝血因子viii的表达载体及其应用
PL3453402T3 (pl)	2012-01-12	2022-03-21	Bioverativ Therapeutics Inc.	Zmniejszenie immunogenności przeciwko czynnikowi viii u osób poddawanych terapii czynnikiem viii
EA035323B1 (ru)	2012-01-12	2020-05-28	Биовератив Терапьютикс Инк.	Полипептиды химерного фактора viii и их применение
HRP20221531T1 (hr)	2012-02-15	2023-02-17	Bioverativ Therapeutics Inc.	Pripravci faktora viii i postupci dobivanja i korištenja istih
LT2822577T (lt)	2012-02-15	2019-03-25	Bioverativ Therapeutics Inc.	Rekombinantiniai faktoriaus viii baltymai
EP2666782A1 (fr) *	2012-05-22	2013-11-27	Imnate Sarl	Facteur VIII de coagulation avec immunogénicité réduite
CA2875246A1 (fr)	2012-06-08	2013-12-12	Biogen Idec Ma Inc.	Composes pro-coagulants
AU2013270683A1 (en)	2012-06-08	2014-12-11	Biogen Ma Inc.	Chimeric clotting factors
WO2014008480A2 (fr)	2012-07-06	2014-01-09	Biogen Idec Ma Inc.	Lignée cellulaire exprimant des polypeptides de facteur viii à une seule chaîne et ses utilisations
US10138291B2 (en)	2012-07-11	2018-11-27	Bioverativ Therapeutics Inc.	Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
EP3970738A1 (fr)	2012-07-25	2022-03-23	Bioverativ Therapeutics Inc.	Essai de surveillance de facteur sanguin et utilisations de celui-ci
CA2888806A1 (fr)	2012-10-18	2014-04-24	Biogen Idec Ma Inc.	Procedes d'utilisation d'une dose fixe d'un facteur de coagulation
HK1214539A1 (zh)	2012-10-30	2016-07-29	Bioverativ Therapeutics Inc.	應用viii因子多肽的方法
US10272163B2 (en)	2012-12-07	2019-04-30	The Regents Of The University Of California	Factor VIII mutation repair and tolerance induction
LT2956477T (lt)	2013-02-15	2021-02-10	Bioverativ Therapeutics Inc.	Optimizuotas faktoriaus viii genas
PL3666283T3 (pl)	2013-03-15	2022-10-03	Bioverativ Therapeutics Inc.	Formulacje polipeptydu czynnika viii
EA037906B1 (ru)	2013-03-15	2021-06-04	Биовератив Терапьютикс Инк.	Препараты полипептида фактора ix
WO2014210558A1 (fr)	2013-06-28	2014-12-31	Biogen Idec Ma Inc.	Lieur pouvant être fendu par thrombine ayant un xten et ses utilisations
EP3043813B1 (fr)	2013-08-08	2021-01-13	Bioverativ Therapeutics Inc.	Purification de molécules chimères du facteur viii
EP3033097B1 (fr)	2013-08-14	2021-03-10	Bioverativ Therapeutics Inc.	Fusions de factor viii-xten et leurs utilisations.
KR20160090810A (ko)	2013-10-22	2016-08-01	디비브이 테크놀로지스 (소시에떼 아노님)	혈액 인자에 대한 관용 유도에 의한 혈우병의 치료 방법
WO2015070014A1 (fr)	2013-11-08	2015-05-14	Biogen Idec Ma Inc.	Composé de fusion procoagulant
EP3082848B1 (fr)	2013-12-06	2023-10-18	Bioverativ Therapeutics Inc.	Outils pharmacocinétiques de population et leurs utilisations
EP2881463A1 (fr)	2013-12-09	2015-06-10	DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH	Variants du facteur IX présentant une activité de coagulation en l'absence de leur cofacteur et/ou à une activité de coagulation F.IX accrue et leur utilisation pour traiter des troubles de saignement
DK3091997T5 (da)	2014-01-10	2024-10-14	Bioverativ Therapeutics Inc	Kimære faktor viii-proteiner og anvendelser deraf
KR102382402B1 (ko)	2014-02-04	2022-04-01	바이오젠 엠에이 인코포레이티드	번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
WO2015127129A1 (fr) *	2014-02-19	2015-08-27	Bloodworks	Variants d'épitopes des lymphocytes t du facteur viii à immunogénicité réduite
EP3114138B1 (fr)	2014-03-05	2021-11-17	Pfizer Inc.	Mutéines améliorées du facteur viii de coagulation
EP3160478A4 (fr)	2014-06-30	2018-05-16	Bioverativ Therapeutics Inc.	Gène du facteur ix optimisé
MA40864A (fr)	2014-10-31	2017-09-05	Biogen Ma Inc	Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
MX2018001497A (es)	2015-08-03	2018-05-15	Bioverativ Therapeutics Inc	Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
PE20231949A1 (es) *	2015-10-30	2023-12-05	Spark Therapeutics Inc	VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
CN116949052A (zh)	2015-11-13	2023-10-27	武田药品工业株式会社	用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
EA036944B1 (ru)	2015-11-13	2021-01-19	Баксалта Инкорпорейтед	Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
PL3411478T3 (pl)	2016-02-01	2022-10-03	Bioverativ Therapeutics Inc.	Geny zoptymalizowanego czynnika VIII
JP6877469B2 (ja)	2016-06-24	2021-05-26	モガム・インスティテュート・フォー・バイオメディカル・リサーチＭｏｇａｍＩｎｓｔｉｔｕｔｅＦｏｒＢｉｏｍｅｄｉｃａｌＲｅｓｅａｒｃｈ	Ｆｖｉｉｉおよびｖｗｆ因子を含むキメラタンパク質、ならびにそれらの使用
WO2018102743A1 (fr)	2016-12-02	2018-06-07	Bioverativ Therapeutics Inc.	Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques
BR112019011198A2 (pt)	2016-12-02	2019-12-17	Bioverativ Therapeutics Inc	métodos de indução de tolerância imune a fatores de coagulação
JP2020519272A (ja)	2017-05-09	2020-07-02	エモリーユニバーシティー	凝固因子変異体及びその使用
JP7374883B2 (ja)	2017-08-09	2023-11-07	バイオベラティブセラピューティクスインコーポレイテッド	核酸分子およびその使用
WO2019152692A1 (fr)	2018-02-01	2019-08-08	Bioverativ Therapeutics, Inc.	Utilisation de vecteurs lentiviraux exprimant le facteur viii
TW202014181A (zh)	2018-04-04	2020-04-16	美商希吉隆醫療公司	可植入顆粒及相關方法
RS66972B1 (sr)	2018-05-18	2025-07-31	Bioverativ Therapeutics Inc	Metode lečenja hemofilije a
KR20210034013A (ko)	2018-07-16	2021-03-29	박스알타 인코퍼레이티드	발현이 증가된 재조합 fviii 변이체들을 인코딩하는 바이러스 벡터를 이용한 혈우병의 유전적 치료법
CN119955796A (zh)	2018-08-09	2025-05-09	比奥维拉迪维治疗股份有限公司	核酸分子及其用于非病毒基因疗法的用途
UY38389A (es)	2018-09-27	2020-04-30	Sigilon Therapeutics Inc	Dispositivos implantables para terapia celular y métodos relacionados
TWI851647B (zh)	2019-01-16	2024-08-11	日商武田藥品工業股份有限公司	用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
CN114007637A (zh)	2019-06-19	2022-02-01	比奥维拉迪维治疗股份有限公司	用于治疗血友病和低骨矿物质密度的重组因子viii-fc
US20200405883A1 (en)	2019-06-20	2020-12-31	Baxalta Incorporated	Method of treatment with viral-based gene therapy
CN115279896A (zh)	2019-09-30	2022-11-01	比奥维拉迪维治疗股份有限公司	慢病毒载体配制品
CN114981299A (zh)	2019-12-12	2022-08-30	武田药品工业株式会社	使用编码具有增加的表达的重组fviii变体的病毒载体的a型血友病的基因疗法
MX2023000156A (es)	2020-06-24	2023-02-16	Bioverativ Therapeutics Inc	Metodos para la eliminacion de factor viii libre de preparaciones de vectores lentivirales modificados para expresar dicha proteina.
TW202246505A (zh) *	2021-03-05	2022-12-01	俄羅斯聯邦商亞那拜恩有限公司	編碼凝血因子ｉｘ蛋白的密碼子優化的核酸及其用途
JP2024514307A (ja) *	2021-03-31	2024-04-01	ヘモネティクス・コーポレーション	血液凝固測定装置の品質管理配合物
US20240269241A1 (en)	2021-06-14	2024-08-15	Takeda Pharmaceutical Company Limited	Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
EP4392443A1 (fr)	2021-08-23	2024-07-03	Bioverativ Therapeutics Inc.	Gènes de facteur viii optimisés
CA3232988A1 (fr)	2021-09-30	2023-04-06	Bioverativ Therapeutics Inc.	Acides nucleiques codant pour des polypeptides du facteur viii a immunogenicite reduite
EP4602155A1 (fr)	2022-10-11	2025-08-20	Sigilon Therapeutics, Inc.	Cellules modifiées et éléments implantables pour le traitement d'une maladie
WO2025008774A1 (fr)	2023-07-05	2025-01-09	Takeda Pharmaceutical Company Limited	Vecteurs viraux codant pour des variants de fviii recombinants ayant une expression accrue pour la thérapie génique de l'hémophilie a

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4757006A (en)	1983-10-28	1988-07-12	Genetics Institute, Inc.	Human factor VIII:C gene and recombinant methods for production
EP0182448A3 (fr)	1984-08-24	1987-10-28	Genetics Institute, Inc.	Production de facteur VIII et produits apparentés
JPH0788399B2 (ja)	1985-04-12	1995-09-27	ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド	新規プロコアギュラント蛋白質
JPH0387173A (ja)	1987-09-10	1991-04-11	Teijin Ltd	ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
DK162233C (da)	1989-11-09	1992-03-16	Novo Nordisk As	Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
AU656720B2 (en) *	1989-12-01	1995-02-16	Gene Pharming Europe Bv	Production of recombinant polypeptides by bovine species and transgenic methods
US6180371B1 (en) *	1996-06-26	2001-01-30	Emory University	Modified factor VIII
US5364771A (en)	1992-04-07	1994-11-15	Emory University	Hybrid human/porcine factor VIII
US5663060A (en)	1992-04-07	1997-09-02	Emory University	Hybrid human/animal factor VIII
US5563045A (en)	1992-11-13	1996-10-08	Genetics Institute, Inc.	Chimeric procoagulant proteins
WO1997003193A1 (fr)	1995-07-11	1997-01-30	Chiron Corporation	Nouveaux analogues du polypeptide du facteur viii:c presentant des proprietes modifiees de liaison avec des metaux
AU6291896A (en)	1995-07-11	1997-02-10	Chiron Corporation	Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains
WO2002024723A1 (fr) *	2000-09-19	2002-03-28	Emory University	Facteur viii modifie
MXPA04005079A (es) *	2001-11-30	2004-08-19	Univ Emory	Variantes del dominio c2 del factor viii.
US7105745B2 (en) *	2002-12-31	2006-09-12	Thomas & Betts International, Inc.	Water resistant electrical floor box cover assembly

2000
- 2000-03-10 US US09/523,656 patent/US6458563B1/en not_active Expired - Lifetime
2001
- 2001-02-16 PL PL359672A patent/PL202936B1/pl unknown
- 2001-02-16 NZ NZ520799A patent/NZ520799A/en not_active IP Right Cessation
- 2001-02-16 RU RU2002124123/13A patent/RU2285724C2/ru active
- 2001-02-16 HU HU0300586A patent/HU227804B1/hu active Protection Beyond IP Right Term
- 2001-02-16 AU AU2001238416A patent/AU2001238416B2/en active Active
- 2001-02-16 SI SI200130823T patent/SI1280540T1/sl unknown
- 2001-02-16 EP EP01910853A patent/EP1280540B1/fr not_active Expired - Lifetime
- 2001-02-16 WO PCT/US2001/005076 patent/WO2001068109A1/fr not_active Ceased
- 2001-02-16 JP JP2001566673A patent/JP4044337B2/ja not_active Expired - Lifetime
- 2001-02-16 KR KR10-2002-7011843A patent/KR100485525B1/ko not_active Expired - Lifetime
- 2001-02-16 EE EEP200200510A patent/EE05075B1/xx active Protection Beyond IP Right Term
- 2001-02-16 MX MXPA02008798A patent/MXPA02008798A/es active IP Right Grant
- 2001-02-16 SK SK1439-2002A patent/SK286205B6/sk not_active IP Right Cessation
- 2001-02-16 BR BR122013026957A patent/BR122013026957A8/pt not_active Application Discontinuation
- 2001-02-16 CA CA2400295A patent/CA2400295C/fr not_active Expired - Lifetime
- 2001-02-16 ES ES01910853T patent/ES2304379T3/es not_active Expired - Lifetime
- 2001-02-16 UA UA2002097145A patent/UA75064C2/uk unknown
- 2001-02-16 RS YUP-680/02A patent/RS50364B/sr unknown
- 2001-02-16 PT PT01910853T patent/PT1280540E/pt unknown
- 2001-02-16 CZ CZ20023346A patent/CZ298250B6/cs unknown
- 2001-02-16 AT AT01910853T patent/ATE391512T1/de active
- 2001-02-16 CN CNB018063179A patent/CN1191360C/zh not_active Expired - Lifetime
- 2001-02-16 AU AU3841601A patent/AU3841601A/xx active Pending
- 2001-02-16 BR BRPI0109131A patent/BRPI0109131B8/pt not_active IP Right Cessation
- 2001-02-16 IL IL15137101A patent/IL151371A0/xx unknown
- 2001-02-16 DK DK01910853T patent/DK1280540T3/da active
- 2001-02-16 DE DE60133541T patent/DE60133541T2/de not_active Expired - Lifetime
- 2001-02-16 ME MEP-2009-82A patent/ME00601B/fr unknown
2002
- 2002-06-28 US US10/187,319 patent/US7012132B2/en not_active Expired - Fee Related
- 2002-08-21 IL IL151371A patent/IL151371A/en active IP Right Grant
- 2002-08-26 ZA ZA200206810A patent/ZA200206810B/en unknown
- 2002-09-09 NO NO20024296A patent/NO331935B1/no not_active IP Right Cessation
2004
- 2004-09-10 US US10/938,414 patent/US7122634B2/en not_active Expired - Fee Related
2008
- 2008-07-07 CY CY20081100709T patent/CY1108179T1/el unknown
2016
- 2016-04-27 LU LU93049C patent/LU93049I2/fr unknown
- 2016-04-29 FR FR16C0016C patent/FR16C0016I2/fr active Active
- 2016-05-02 BE BE2016C024C patent/BE2016C024I2/fr unknown
- 2016-05-06 LT LTPA2016014C patent/LTC1280540I2/lt unknown
- 2016-05-09 HU HUS1600020C patent/HUS1600020I1/hu unknown
- 2016-05-09 NL NL300808C patent/NL300808I2/nl unknown
- 2016-05-10 CY CY2016011C patent/CY2016011I2/el unknown
- 2016-05-10 NO NO2016007C patent/NO2016007I1/no unknown

Also Published As

Publication number	Publication date
NO20024296D0 (no)	2002-09-09
RU2285724C2 (ru)	2006-10-20
ZA200206810B (en)	2003-11-26
ES2304379T3 (es)	2008-10-16
RS50364B (sr)	2009-11-10
SI1280540T1 (sl)	2008-08-31
CN1191360C (zh)	2005-03-02
BR122013026957A8 (pt)	2017-02-21
SK286205B6 (sk)	2008-05-06
NO20024296L (no)	2002-11-08
EE200200510A (et)	2004-02-16
PT1280540E (pt)	2008-06-09
IL151371A0 (en)	2003-04-10
AU3841601A (en)	2001-09-24
PL359672A1 (en)	2004-09-06
ATE391512T1 (de)	2008-04-15
CY2016011I1 (el)	2016-10-05
BE2016C024I2 (fr)	2020-01-30
HUP0300586A3 (en)	2006-11-28
EP1280540A4 (fr)	2004-11-03
US20030068785A1 (en)	2003-04-10
SK14392002A3 (sk)	2003-06-03
NO2016007I2 (no)	2016-05-10
MEP8209A (en)	2011-12-20
RU2002124123A (ru)	2004-03-27
KR20020081426A (ko)	2002-10-26
HUP0300586A2 (hu)	2003-06-28
CZ298250B6 (cs)	2007-08-01
BR122013026957A2 (fr)	2004-12-07
EP1280540B1 (fr)	2008-04-09
DE60133541T2 (de)	2009-05-07
FR16C0016I1 (fr)	2016-04-29
NO331935B1 (no)	2012-05-07
AU2001238416B2 (en)	2004-09-02
BRPI0109131B1 (pt)	2020-08-25
NL300808I1 (fr)	2016-05-18
HK1051004A1 (en)	2003-07-18
WO2001068109A1 (fr)	2001-09-20
US7122634B2 (en)	2006-10-17
FR16C0016I2 (fr)	2018-11-02
US7012132B2 (en)	2006-03-14
IL151371A (en)	2010-12-30
US20050079584A1 (en)	2005-04-14
HUS1600020I1 (hu)	2016-06-28
CZ20023346A3 (cs)	2003-01-15
DE60133541D1 (de)	2008-05-21
LU93049I2 (fr)	2016-06-27
JP2003526358A (ja)	2003-09-09
EE05075B1 (et)	2008-10-15
HU227804B1 (en)	2012-03-28
CN1416348A (zh)	2003-05-07
BRPI0109131B8 (pt)	2021-07-06
NZ520799A (en)	2004-06-25
UA75064C2 (en)	2006-03-15
BR0109131A (pt)	2004-12-07
NO2016007I1 (no)	2016-05-10
KR100485525B1 (ko)	2005-04-28
CY2016011I2 (el)	2016-10-05
JP4044337B2 (ja)	2008-02-06
YU68002A (sh)	2005-11-28
US6458563B1 (en)	2002-10-01
CY1108179T1 (el)	2014-02-12
LTC1280540I2 (lt)	2020-05-25
CA2400295A1 (fr)	2001-09-20
CA2400295C (fr)	2012-01-10
PL202936B1 (pl)	2009-08-31
NL300808I2 (nl)	2020-12-21
ME00601B (fr)	2011-12-20
MXPA02008798A (es)	2003-04-25
EP1280540A1 (fr)	2003-02-05

Publication	Publication Date	Title
ATE391512T1 (de)	2008-04-15	Modifizierter faktor viii
DE60019122D1 (de)	2005-05-04	Veränderter faktor viii
DK1200418T3 (da)	2004-07-26	Nematodicide trifluorbutener
ATE250605T1 (de)	2003-10-15	Piperidin verbindung zur behandlung von psoriasis
DE60126980D1 (de)	2007-04-12	Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE254461T1 (de)	2003-12-15	Behandlung von augenschmerzen
MXPA04005079A (es)	2004-08-19	Variantes del dominio c2 del factor viii.
ATE389395T1 (de)	2008-04-15	Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
ATE217889T1 (de)	2002-06-15	Humane antikörper gegen faktor ix/ixa
CY1106026T1 (el)	2011-04-06	Αρυλσουλφοναμιδια ως ανταγωνιστες της σepοτονινης για την αγωγη της παχυσαρκιας
NO20025405D0 (no)	2002-11-11	Modulatorer for TNF-alfa-signalisering
DE60036122D1 (de)	2007-10-04	Verwendung von eplerenon zur behandlung von restenose
DE50010234D1 (de)	2005-06-09	Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
DE60142786D1 (de)	2010-09-23	Zusammensetzungen und methoden zur behandlung von candidosen
ATE274513T1 (de)	2004-09-15	Verbindungen und verfahren zur behandlung von schmerz
ATE344662T1 (de)	2006-11-15	Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
CY1105142T1 (el)	2009-11-04	Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
DE60313005D1 (de)	2007-05-16	Behandlung von dyskinesie mit 2,3-benzodiazepinen
ATE226443T1 (de)	2002-11-15	Verwendung von orosomucoid zur herstellung einer pharmazeutischen präparation zur behandlung von pankreatitis